do Carmo Silva Lívia, de Oliveira Amanda Alves, de Souza Dienny Rodrigues, Barbosa Katheryne Lohany Barros, Freitas E Silva Kleber Santiago, Carvalho Júnior Marcos Antonio Batista, Rocha Olívia Basso, Lima Raisa Melo, Santos Thaynara Gonzaga, Soares Célia Maria de Almeida, Pereira Maristela
Laboratory of Molecular Biology, Institute of Biological Sciences, Federal University of Goiás, Goiânia 74690-900, GO, Brazil.
Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, GO, Brazil.
J Fungi (Basel). 2020 Nov 19;6(4):300. doi: 10.3390/jof6040300.
Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from , with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM.
副球孢子菌病是一种被忽视的疾病，会造成经济和社会影响，主要影响某些社会阶层的人群，如农村工人。抗真菌药物的局限性，如毒性、药物相互作用、给药途径受限以及在靶组织中的生物利用度降低，在临床环境中已变得很明显。这些因素，再加上副球孢子菌病（PCM）治疗是一个漫长的过程，持续数月至数年，凸显了研发新分子的必要性。研究人员集中精力使用多种工具鉴定新化合物，并针对来自[具体来源未明确]的重要蛋白质，重点关注人类不存在的酶促途径。本综述旨在讨论在提出针对PCM的新型抗真菌药物时，与化合物鉴定、方法和前景相关的方面。
